Mike, appreciate your insights. Any thoughts on AMBS? Feels like they are on the right track. I am big holder(it's all relative right.). Thx
My pleasure...it was a bit of a leap, but the reason just jumped off the page at me as to what he was doing with this. There is no doubt a lot more to this and I might be wrong . There should be many labs looking to configure various protocols. You do not want to suck up BOD(others) time w/every single IUO/RUO interface that walks in the door. Well anyways, this is a positive step and not typical to a lab rat /academic organization.
No, you don't. It is reference to management 101, how to produce a product. AMBS has a lot of tech tools in the shed but has not yet put th resources/plans (internally) to convert the technology into product/stuff that people will buy/use. This is a basic step required to operationalize-link with Pharma producers/researchers. (Where do I go to start to use LYMPRO?) The last step in product development is transfer to operations/production. In the case of LYMPRO that is RUO/IUO pharma teams who need someplace to go for the next step. That is what this new function will provide...the LINK for transfer. Hence the ref to basics...blocking and tackleing....football-business basics
With any continued luck, they will be bought for big $$$ long before they run out of $$$. Look at ONXX as example...which I was in at 14 and sold at 127+....great
You nailed it. These are smart, hard working people who (just maybe) are now going to be able to leverage their respective backgrounds and knowledge. If they can focus on results that are measureable and move their respective hypothesis while doing so then the collaborative work will overwhelm political differences. When things can be measured(LYMPRO) stuff happens. All the best.
That is what I was thinking, a new challenge and set of variables. Specifically, how will injuries and respective treatments impact recovery and effectiveness of scaffold? Well, it is what it is, let's hope the patient does well. It is all w/in the scope of the device.
Impressive...and it's about time. Hundreds of academics and pharma and big thinkers working independently have not produced much of anything. How about a focused group who will decide, direct, guide and collaborate to diagnose and measure people who are ill. EXCELLENT.
"marketing of our blood-based markers to the IUO market. They will be of great assistance as we work with pharmaceutical companies to improve their Alzheimer's therapeutics development programs, which have had a disappointing 99.6% failure rate, in large part due to an inability to properly screen patients prior to study enrollment, as well as difficulty in monitoring the effectiveness of drug activity on disease-relevant biomarkers"
AND.....99.6 % failure is absolutely unacceptable. NOW, FIX IT.
The product development process is continuously evolveing. There is a common language and a similar development platform. I would now expect they have to agree on milestones, a path for trials and consolidation of gains. SOMETHING is going to happen, just what and when has to be reset. Resource needs have got to be on the table now.
Been here for a couple+ years and have a sense of rfustration also, but so far I am not pulling the plug.
AMBS is a leap of faith. We all understand that. We do our DD, model some scenario with varying degrees of sophistication. But, none of us really knows what is going on. For me, Lympro delivery represents the difference bewteen an organization capable of actually delivering a product vs one that continuously talks about delivering a product. We are paying for the learning process at AMBS. It is said that learning occurs at the fringe of knowledge, that is what just happened and will continue with G-town. Good, we expect that to. We want and expect AMBS to produce a product or service even while learning is happening. SP will be limited when the product is learning ONLY. That is about as far as faith gets us, we are all constrained as humans by time. MANF on the other hand is the gift that keeps on giving. MANF WILL present one continuous (AKA-meaning of life) learning process. IMO, LYMPRO = credibility for BOD and AMBS, AMBS would be a scam if it was dangling LYMPRO to buy time while everyone is REALLY focused on MANF. If that is not true then it is time to prove it. MANF is massive ($100 SP), LYMPRO is x's and O's, blocking and tackleling.